Previous 10 | Next 10 |
Gainers: Novan (NOVN) +81%, Aptinyx (APTX) +25%, Vaxart (VXRT) +39%, Progenity (PROG) +28%, Chemomab Therapeutics (CMMB) +9%.Losers: Orphazyme (ORPH) -41%, Curis (CRIS) -32%, Aptose Biosciences (APTO) -30%, Galecto (GLTO) -22%,&...
Amesite (AMST) +61%.GBS (GBS) +40%.Novan (NOVN) +37% on positive results for SB206 in skin infection.Precigen (PGEN) +31% on positive topline results from phase 1b/2a study of AG019 ActoBiotics™.Protagenic Therapeutics (PTIX) +28%.Magnachip Semiconductor Corporation (MX) +24%...
The following slide deck was published by Aptinyx Inc. in conjunction with this event. For further details see: Aptinyx Investor Presentation - Slideshow
Image source: The Motley Fool. Aptinyx Inc. (NASDAQ: APTX) Q1 2021 Earnings Call May 13, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Aptinyx Inc. (APTX) Q1 2021 Earnings Call Transcript
Aptinyx Inc. (APTX) Q1 2021 Earnings Conference Call May 13, 2021, 05:00 PM ET Company Participants Nick Smith - VP of Corporate Development & IR Norbert Riedel - CEO Ashish Khanna - CFO & CBO Andy Kidd - President & COO Kathryn King - SVP of Clinical Development Harald Murck - VP...
Aptinyx (APTX): Q1 GAAP EPS of -$0.22 misses by $0.01.Revenue of $1M (+23.5% Y/Y)Press Release For further details see: Aptinyx EPS misses by $0.01
Enrollment on track in both Phase 2b studies of NYX-2925 in chronic pain — data readouts expected 1H 2022 Preparing for NYX-783 Phase 2b PTSD study following recent FDA meeting — study initiation expected in 2H 2021 Recommenced Phase 2 study of NY...
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the election of Joan W. Miller, M.D., to the company’s Board of Directors. Dr. Miller currently ser...
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, May 13, 2021 at 5:00 p.m. ET to...
Aptinyx (APTX) presents additional data from its exploratory Phase 2 study of NYX-783 in patients with post-traumatic stress disorder ((PTSD)). The study, enrolling 153 patients, consisted of two four-week treatment stages comparing once-daily oral dosing of NYX-783—10mg or 50mg—...
News, Short Squeeze, Breakout and More Instantly...
Signature Bank (SBNY) is expected to report for Q3 2023 BHP Group Ltd. (BHP) is expected to report for Q1 2024 Sorrento Therapeutics Inc. (SRNEQ) is expected to report $-0.15 for Q3 2023 Baran Group Ltd. (BRANF) is expected to report for quarter end 2023-09-30 World Copper (WCUFF)...
GLG Life Tech Corporation (GLGLF) is expected to report for Q1 2024 Accenture plc Class A (Ireland) (ACN) is expected to report $3.14 for Q1 2024 Greenlane Holdings Inc. (GNLN) is expected to report $-2.7 for Q3 2023 iMedia Brands Inc. (IMBIQ) is expected to report for quarter end 202...
Axcella Health Inc. (AXLA) is expected to report for Q3 2023 Telekom Malaysia Bhd (MYTEF) is expected to report for quarter end 2023-09-30 Atento S.A. (ATTOF) is expected to report for Q3 2023 Scryb Inc Com (SCYRF) is expected to report for Q4 2023 BHP Group Ltd. (BHP) is expected...